CHARLES SCHWAB INVESTMENT MANAGEMENT INC - ZIOPHARM ONCOLOGY INC ownership

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of ZIOPHARM ONCOLOGY INC
ValueSharesWeighting
Q3 2023$14,537
-74.2%
110,2970.0%0.00%
Q2 2023$56,251
+4.4%
110,297
+32.9%
0.00%
Q4 2022$53,859
-62.3%
82,9750.0%0.00%
Q3 2022$143,000
+38.8%
82,9750.0%0.00%
Q2 2022$103,000
-70.8%
82,975
-84.6%
0.00%
Q1 2022$353,000
-40.2%
540,5420.0%0.00%
Q4 2021$590,000
-38.0%
540,542
+3.4%
0.00%
Q3 2021$952,000
-75.6%
522,983
-64.6%
0.00%
-100.0%
Q2 2021$3,904,000
-26.2%
1,478,785
+0.7%
0.00%
-50.0%
Q1 2021$5,288,000
+47.8%
1,468,765
+3.5%
0.00%
+100.0%
Q4 2020$3,577,000
+2.0%
1,419,101
+1.9%
0.00%
-50.0%
Q3 2020$3,508,000
-19.6%
1,392,013
+4.7%
0.00%0.0%
Q2 2020$4,361,000
+51.3%
1,329,337
+13.0%
0.00%0.0%
Q1 2020$2,883,000
-39.0%
1,176,653
+17.6%
0.00%
-33.3%
Q4 2019$4,723,000
+12.9%
1,000,527
+2.4%
0.00%
+50.0%
Q3 2019$4,182,000
-20.2%
976,974
+8.7%
0.00%
-33.3%
Q2 2019$5,239,000
+63.0%
898,615
+7.6%
0.00%
+50.0%
Q1 2019$3,215,000
+131.0%
834,853
+12.2%
0.00%
+100.0%
Q4 2018$1,392,000
-35.9%
743,958
+9.7%
0.00%0.0%
Q3 2018$2,171,000
+0.7%
678,307
-5.0%
0.00%
-50.0%
Q2 2018$2,156,000
-17.2%
713,837
+7.5%
0.00%0.0%
Q1 2018$2,604,000
-2.4%
664,222
+3.0%
0.00%0.0%
Q4 2017$2,669,000
-29.7%
644,642
+4.2%
0.00%
-33.3%
Q3 2017$3,799,000
+5.3%
618,589
+6.6%
0.00%0.0%
Q2 2017$3,609,000
+5.7%
580,149
+7.8%
0.00%0.0%
Q1 2017$3,413,000
+25.0%
538,289
+5.5%
0.00%0.0%
Q4 2016$2,731,000
-1.7%
510,383
+3.5%
0.00%0.0%
Q3 2016$2,777,000
+8.0%
493,146
+5.3%
0.00%0.0%
Q2 2016$2,572,000
-24.4%
468,322
+2.1%
0.00%
-25.0%
Q1 2016$3,404,000
-4.6%
458,650
+6.8%
0.00%
-20.0%
Q4 2015$3,568,000
-2.1%
429,259
+6.2%
0.01%0.0%
Q3 2015$3,644,000
-26.7%
404,375
-2.3%
0.01%
-28.6%
Q2 2015$4,968,000
+28.4%
413,926
+15.3%
0.01%
+40.0%
Q1 2015$3,868,000
+109.8%
359,059
-1.3%
0.01%
+66.7%
Q4 2014$1,844,000
+62.5%
363,689
-15.4%
0.00%
+50.0%
Q3 2014$1,135,000
-24.4%
429,737
+15.4%
0.00%
-33.3%
Q2 2014$1,501,000
+25.2%
372,247
+42.3%
0.00%
+50.0%
Q1 2014$1,199,000
+37.8%
261,607
+30.6%
0.00%0.0%
Q4 2013$870,000
+24.1%
200,273
+20.1%
0.00%
+100.0%
Q3 2013$701,000
+96.4%
166,725
-1.2%
0.00%0.0%
Q2 2013$357,000168,7310.00%
Other shareholders
ZIOPHARM ONCOLOGY INC shareholders Q4 2023
NameSharesValueWeighting ↓
Third Security, LLC 9,709,607$60,394,0003.07%
MSD Partners, L.P. 3,410,500$21,213,0001.32%
MILLER VALUE PARTNERS, LLC 4,926,456$30,643,0001.24%
Michael & Susan Dell Foundation 66,749$415,0000.33%
ACUTA CAPITAL PARTNERS, LLC 150,000$933,0000.26%
Piermont Capital Management Inc. 85,500$532,0000.15%
A.R.T. Advisors, LLC 411,547$2,559,0000.14%
EQUITEC PROPRIETARY MARKETS, LLC 96,100$598,0000.14%
Vident Investment Advisory, LLC 204,744$1,274,0000.10%
EQUITEC PROPRIETARY MARKETS, LLC 68,800$428,0000.10%
View complete list of ZIOPHARM ONCOLOGY INC shareholders